Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo

During the 2018–2020 Ebola virus disease outbreak in Democratic Republic of the Congo, a phase 3 trial of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine (DRC-EB-001) commenced in Goma, with participants being offered the two-dose regimen given 56 days apart. Suspension of trial activities in 2020 due to...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Vaccines Ročník 12; číslo 8; s. 828
Hlavní autoři: Choi, Edward Man-Lik, Kasonia, Kambale, Kavunga-Membo, Hugo, Mukadi-Bamuleka, Daniel, Soumah, Aboubacar, Mossoko, Zephyrin, Edwards, Tansy, Tetsa-Tata, Darius, Makarimi, Rockyath, Toure, Oumar, Mambula, Grace, Brindle, Hannah, Camacho, Anton, Connor, Nicholas E., Mukadi, Pierre, McLean, Chelsea, Keshinro, Babajide, Gaddah, Auguste, Robinson, Cynthia, Luhn, Kerstin, Foster, Julie, Roberts, Chrissy h., Johnson, John Emery, Imbault, Nathalie, Bausch, Daniel G., Grais, Rebecca F., Watson-Jones, Deborah, Muyembe-Tamfum, Jean Jacques
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland MDPI AG 23.07.2024
MDPI
Témata:
Adenoviruses
Adolescents
Adults
Age groups
Antibodies
Children
Consortia
COVID-19
COVID-19 vaccines
Democratic Republic of the Congo
DRC
Ebola
Ebola virus
Ebolavirus
Enzyme-linked immunosorbent assay
Epidemics
Glycoproteins
Hypothesis testing
Immunization
Immunogenicity
Immunoglobulin G
Laboratories
Medicine
outbreak
Pandemics
Public health
R
Sample size
Teenagers
vaccine
Vaccines
Viral diseases
Viruses
Ankara Turkey
Turkey
Belgium
Congo-Democratic Republic of Congo
United States > US
San Juan Capistrano California
vaccine
DRC
Mvabea
Zabdeno
Ad26.ZEBOV
MVA-BN-Filo
outbreak
interval
Democratic Republic of the Congo
Ebola
immunogenicity
ISSN:2076-393X, 2076-393X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:During the 2018–2020 Ebola virus disease outbreak in Democratic Republic of the Congo, a phase 3 trial of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine (DRC-EB-001) commenced in Goma, with participants being offered the two-dose regimen given 56 days apart. Suspension of trial activities in 2020 due to the COVID-19 pandemic led to some participants receiving a late dose 2 outside the planned interval. Blood samples were collected from adults, adolescents, and children prior to their delayed dose 2 vaccination and 21 days after, and tested for IgG binding antibodies against Ebola virus glycoprotein using the Filovirus Animal Nonclinical Group (FANG) ELISA. Results from 133 participants showed a median two-dose interval of 9.3 months. The pre-dose 2 antibody geometric mean concentration (GMC) was 217 ELISA Units (EU)/mL (95% CI 157; 301) in adults, 378 EU/mL (281; 510) in adolescents, and 558 EU/mL (471; 661) in children. At 21 days post-dose 2, the GMC increased to 22,194 EU/mL (16,726; 29,449) in adults, 37,896 EU/mL (29,985; 47,893) in adolescents, and 34,652 EU/mL (27,906; 43,028) in children. Participants receiving a delayed dose 2 had a higher GMC at 21 days post-dose 2 than those who received a standard 56-day regimen in other African trials, but similar to those who received the regimen with an extended interval.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These authors contributed equally to this work.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines12080828